2009
Stixová, Lenka; Procházková, Jirina; Soucek, Karel; Hofmanová, Jirina; Kozubík, Alois
5-Lipoxygenase inhibitors potentiate 1alpha,25-dihydroxyvitamin D3-induced monocytic differentiation by activating p38 MAPK pathway. Journal Article
In: Molecular and cellular biochemistry, vol. 330, no. 1-2, pp. 229–238, 2009, ISSN: 1573-4919 0300-8177, (Place: Netherlands).
Abstract | Links | BibTeX | Tags: Arachidonate 5-Lipoxygenase/*genetics, Benzoquinones/pharmacology, Cell Differentiation/*drug effects, HL-60 Cells, Humans, Indoles/pharmacology, Lipoxygenase Inhibitors/*pharmacology, Monocytes/*cytology, p38 Mitogen-Activated Protein Kinases/*metabolism, Vitamin D/*analogs & derivatives/pharmacology
@article{stixova_5-lipoxygenase_2009,
title = {5-Lipoxygenase inhibitors potentiate 1alpha,25-dihydroxyvitamin D3-induced monocytic differentiation by activating p38 MAPK pathway.},
author = {Lenka Stixová and Jirina Procházková and Karel Soucek and Jirina Hofmanová and Alois Kozubík},
doi = {10.1007/s11010-009-0138-x},
issn = {1573-4919 0300-8177},
year = {2009},
date = {2009-10-01},
journal = {Molecular and cellular biochemistry},
volume = {330},
number = {1-2},
pages = {229–238},
abstract = {The treatment of human promyelocytic leukemia cell lines HL-60, and to some extent NB-4, with 1alpha,25-dihydroxyvitamin D(3) (VD3) induces differentiation toward the monocytic/macrophage lineage, demonstrated by the increased expression of CD11b and CD14, and the production of opsonized zymosan particles (OZP)-stimulated reactive oxygen species (ROS). Moreover, in more sensitive HL-60 cells, increased expression of 5-lipoxygenase (5-LPO), Mcl-1, IkappaB, and c-Jun, accompanied by the activation of p38 MAPK, was detected. These VD3 effects on HL-60 cell differentiation were significantly potentiated by 5-LPO inhibitors MK-886 and AA-861 and were inverted by SB202190 (SB), a p38 MAPK inhibitor. The inhibition of differentiation by SB was demonstrated by a reduction of CD14 expression and by a decrease in OZP-activated ROS production. These results indicated that p38 MAPK pathway is involved in 5-LPO inhibitors-dependent potentiation of VD3-induced monocytic differentiation.},
note = {Place: Netherlands},
keywords = {Arachidonate 5-Lipoxygenase/*genetics, Benzoquinones/pharmacology, Cell Differentiation/*drug effects, HL-60 Cells, Humans, Indoles/pharmacology, Lipoxygenase Inhibitors/*pharmacology, Monocytes/*cytology, p38 Mitogen-Activated Protein Kinases/*metabolism, Vitamin D/*analogs & derivatives/pharmacology},
pubstate = {published},
tppubtype = {article}
}
The treatment of human promyelocytic leukemia cell lines HL-60, and to some extent NB-4, with 1alpha,25-dihydroxyvitamin D(3) (VD3) induces differentiation toward the monocytic/macrophage lineage, demonstrated by the increased expression of CD11b and CD14, and the production of opsonized zymosan particles (OZP)-stimulated reactive oxygen species (ROS). Moreover, in more sensitive HL-60 cells, increased expression of 5-lipoxygenase (5-LPO), Mcl-1, IkappaB, and c-Jun, accompanied by the activation of p38 MAPK, was detected. These VD3 effects on HL-60 cell differentiation were significantly potentiated by 5-LPO inhibitors MK-886 and AA-861 and were inverted by SB202190 (SB), a p38 MAPK inhibitor. The inhibition of differentiation by SB was demonstrated by a reduction of CD14 expression and by a decrease in OZP-activated ROS production. These results indicated that p38 MAPK pathway is involved in 5-LPO inhibitors-dependent potentiation of VD3-induced monocytic differentiation.